The 4 big myeloma randomized trials to watch out for ASCO #ASCO24 1. Isa-VRd vs Isa-Rd newly diagnosed 2.Isa-VRd vs VRd (IMROZ) 3.DREAMM8 Bela-Pd vs Pd 4.Ven Dex vs Pom Dex (Canova) See thread for why they are important.

🚨 Out now DREAMM-7 from NEJM BVd vs DVd NEJM Full disclosure: I am a co-author 🧵 BVd vs DVd in early relapse myeloma: N=494 (BVd, n=243; DVd, n=251) Median follow-up 28.2 months  Median Age: 65 High risk cytogenetics: 17% EMD: 5% vs 10% mLOT: 1 Prior dara 1% vs 2% PI

It’s coming thick and fast in all the MM from #ASCO24 NEJM = New England journal of myeloma ! So much to digest and think about and many more options coming for patients. Belantamab 1st line combo phIII trials going to recruit rapidly !

HUGE news for UK myeloma ! Brilliant for patients , available at 4th line before pom. Need to work closely with pharmacy/ ward / ambulatory care teams to safely deliver ramp up doses , minimise early tox but limit number of inpatient days.

Thanks v much Manni Mohyuddin carefully considered and clear , as ever . I’m just wondering now for those isolated 1q21 at diagnosis 65 ish - 70 , whether to can ASCT for good now , lots of nuance here of course to consider

Great opportunity to work for a year with the wonderful heamatology team here OUH - developing our CAR T-cell service. Look forward to your application! nhsjobs.com/job/UK/Oxfords…

Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients In The Maintenance Era: Real-world Results From The Canadian Myeloma Research Group Database Transplantation and Cellular Therapy Journal astctjournal.org/article/S2666-…

PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia buff.ly/3MieaKm Jaimal Kothari Toby Eyre Kush Ediri

A wonderful day playing cricket raising money for OUH and spending time with wonderful friends and colleagues . Some brilliant performances @manil1980 Shaheel Bhuva . Thanks so much to the royal household for hosting us .

Thanks so much for having me - really enjoyed it !

Come by on Monday afternoon to the myeloma CAR-T session to hear more! #ASH24

Lewis et al - ENRICH trial: Ibr+R vs R-chemo 1L MCL - >60y, R-CHOP or R-benda as control - Signif PFS adv for IR esp when R-CHOP is control - Cardiac AEs 22% in IR arm - Blastoid did less well with IR First trial of chemo-free vs chemo in 1L MCL: it's positive! #ASH24

#ASH24 Impressive real-world data from the Greek myeloma group suggesting that sustained MRD negativity for 3 years can guide discontinuation of lenalidomide maintenance, probably except in patients with +2 high risk cytogenetics. #mmsm Thanos Dimopoulos

Our data on whole body composition analysis showing low muscle mass and small lung volumes are associated with increased mortality with BCMA bispecifics. Congratulations to our outstanding Fellow, Charles Agbuduwe and winner of UK Myeloma Society award. UCLH #ASH24 #mmsm

#ASH24 #mmsm Few important observations on AQUILA This is in top of prior observations I shared 🧵

I’m delighted to announce the launch of The Myeloma Minutes podcast , for all those affected by myeloma . Im co-hosting with my brilliant friend and colleague Dr Sally Moore. New content every Thursday , available on all major podcast hosting platforms. themyelomaminutes.podbean.com

STILL TIME TO REGISTER👇 💥 A fantastic, unique event uniting pts, carers, clinicians & pt organisations- across all blood disorders. May 9th - Westminster Info, fantastic agenda & registration - click HPCC25- patientcongress.com If you’re a HCP - register via KOL25 tab